Recently, a newly listed company in the pharmaceutical field has attracted widespread attention from investors. The company just logged in to the A-share market in August 2024, but its performance after listing has been surprising.

From the stock price trend, the company's performance after going public has been relatively stable, without significant fluctuations. However, what truly surprised the market was its bold dividend decision. It is reported that the company's net profit in 2024 is only 200 million yuan, yet it decided to distribute up to 240 million yuan in dividends, a move that undoubtedly showcases the management's courage and confidence.

For a company that has been listed for less than a year, such a generous dividend policy is indeed rare. This not only demonstrates the company's confidence in its future development but also conveys a positive signal to investors. This move may be intended to show that the company has the ability to ensure sustainable business development while also creating substantial returns for shareholders.

However, such a high proportion of dividends has also raised some questions: Does the company have sufficient cash flow to support such a large dividend? Is this dividend policy sustainable? Will the company's future development be affected by this? These questions are worth further attention and research by investors.

Overall, the company's move has caused quite a stir in the pharmaceutical industry. Compared to its peers, Heng Rui Medicine and Mindray Medical, this newly listed company's dividend policy appears to be more aggressive. Whether it can achieve sustainable and stable growth while maintaining high dividends in the future will become a focal point of market attention. While investors keep an eye on this stock, they also need to cautiously assess its long-term investment value.